France · Delayed Price · Currency is EUR MedinCell Statistics
Total Valuation
MedinCell has a market cap or net worth of EUR 965.10 million. The enterprise value is 935.31 million.
| Market Cap | 965.10M |
| Enterprise Value | 935.31M |
Important Dates
The last earnings date was Tuesday, June 16, 2026.
| Earnings Date | Jun 16, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MedinCell has 35.90 million shares outstanding.
| Current Share Class | 35.90M |
| Shares Outstanding | 35.90M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 4.06% |
| Owned by Institutions (%) | 22.01% |
| Float | 32.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 39.75 |
| PB Ratio | 314.98 |
| P/TBV Ratio | 314.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 38.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.67, with a Debt / Equity ratio of 17.96.
| Current Ratio | 4.67 |
| Quick Ratio | 4.10 |
| Debt / Equity | 17.96 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.77 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -13.06% |
| Return on Invested Capital (ROIC) | -23.78% |
| Return on Capital Employed (ROCE) | -23.75% |
| Weighted Average Cost of Capital (WACC) | 9.63% |
| Revenue Per Employee | 173,407 |
| Profits Per Employee | -223,479 |
| Employee Count | 145 |
| Asset Turnover | 0.24 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -69,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +67.58% in the last 52 weeks. The beta is 1.00, so MedinCell's price volatility has been similar to the market average.
| Beta (5Y) | 1.00 |
| 52-Week Price Change | +67.58% |
| 50-Day Moving Average | 27.08 |
| 200-Day Moving Average | 26.55 |
| Relative Strength Index (RSI) | 47.58 |
| Average Volume (20 Days) | 117,383 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MedinCell had revenue of EUR 24.28 million and -31.29 million in losses.
| Revenue | 24.28M |
| Gross Profit | 24.28M |
| Operating Income | -20.74M |
| Pretax Income | -31.36M |
| Net Income | -31.29M |
| EBITDA | -20.05M |
| EBIT | -20.74M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 84.82 million in cash and 55.03 million in debt, with a net cash position of 29.80 million or 0.83 per share.
| Cash & Cash Equivalents | 84.82M |
| Total Debt | 55.03M |
| Net Cash | 29.80M |
| Net Cash Per Share | 0.83 |
| Equity (Book Value) | 3.06M |
| Book Value Per Share | n/a |
| Working Capital | 76.02M |
Cash Flow
| Operating Cash Flow | -24.55M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 691,000 |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -85.44% and -128.88%.
| Gross Margin | 100.00% |
| Operating Margin | -85.44% |
| Pretax Margin | -129.16% |
| Profit Margin | -128.88% |
| EBITDA Margin | -82.60% |
| EBIT Margin | -85.44% |
| FCF Margin | n/a |
Dividends & Yields
MedinCell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -3.24% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for MedinCell is 34.51, which is 28.39% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 34.51 |
| Price Target Difference | 28.39% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 61.29% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |